Development of Balcinrenone/Dapagliflozin Combination in Chronic Kidney Disease

• Pre-clinical efficacy of balcinrenone, a novel MRA with a differentiated mode of action
• In phase 2 trials, balcinrenone/dapagliflozin was safe and reduced albuminuria in patients with CKD, with minor impacts on serum potassium levels
• Phase 3 development in heart failure and CKD

Speakers:

Joseph Kupferman

Global Clinical Head

AstraZeneca